NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.

Autor:	Kriachok I; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Tytorenko I; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Shudrak N; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Aleksik O; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Stepanishyna Y; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Kadnikova T; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Pastushenko Y; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Shokun N; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Rudiyk T; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine., Bushuieva M; State Non-commercial Enterprise 'National Cancer Institute', Kyiv, Ukraine.
Jazyk:	angličtina
Zdroj:	Experimental oncology [Exp Oncol] 2024 Feb 03; Vol. 45 (4), pp. 474-482. Date of Electronic Publication: 2024 Feb 03.
DOI:	10.15407/exp-oncology.2023.04.474
Abstrakt:	Background: The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response. Patients and Methods: An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP - cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18). Results: The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (> 65%) was a negative prognostic factor. Conclusions: The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu